A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Former Google CEO Eric Schmidt believes AI's rapid advancement, already handling 10-20% of programming tasks, signals the end ...

The reported valuation aligns with where Manus had been headed before Meta intervened. The company had been raising new funds ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Not for distribution to U.S. news wire services or dissemination in the United States. VANCOUVER, British Columbia, Dec. 30, ...